Lung cancer remains the leading cause of cancer-related death worldwide, with over two million new cases annually. Advances in molecular biology and immuno-oncology have fundamentally transformed treatment strategies. Comprehensive genomic profiling has enabled precision medicine approaches, allowing the selection of targeted therapies based on driver alterations such as EGFR, ALK, and HER2. For EGFR-mutant NSCLC, sequential development of tyrosine kinase inhibitors (TKIs) from first- to third-generation agents―culminating in osimertinib―has markedly improved survival. Similarly, successive generations of ALK inhibitors, including alectinib, brigatinib, and lorlatinib, have extended disease control, particularly within the central nervous system. The introduction of antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan for HER2-mutant NSCLC, and emerging TKIs like zongertinib, represent new therapeutic milestones.
Shukuya et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: